

May 14, 2013



Quick-Med Announces Expanded Global Distribution of Advanced Dressings With NIMBUS ® Technology

Viridis BioPharma Will Provide Microfoam™ Advanced Wound Care Dressings to Russia and CIS Countries Through Unique Pharmaceutical Labs

GAINESVILLE, FL -- (Marketwired) -- 05/14/13 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that Viridis BioPharma Pvt. Ltd. has been granted an expanded license to sell Microfoam™ dressings. Microfoam is the first advanced wound care dressing to utilize Quick-Med's proprietary non-leaching NIMBUS® technology.

Viridis will have the right to sell the Microfoam dressings it produces under license from Quick-Med to territories now including the Commonwealth of Independent States (CIS). Countries within the expanded territory include Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Uzbekistan, as well as Georgia, Turkmenistan and the Ukraine. Distribution into these territories will be handled by Unique Pharmaceutical Labs, a company based in India, that has an extensive sales and commercial networks in the territories granted. The regulatory clearance process is already underway for Russia, with others following. This expanded contract has a term of 5 years. The core contract between Viridis and QMT that permits manufacture and sale in India of foam and gauze NIMBUS products is extended for the same period.

"We are extremely excited to continue the expansion of this unique technology further into emerging markets," said Bernd Liesenfeld, Quick-Med's president. "These emerging

markets are seeing increasing investments in health care, and their fast growing wound care markets represent a significant opportunity for Viridis to provide patients and caregivers with a great product, and to drive sales with our unique, value-added NIMBUS antimicrobial feature. This technology can succeed in these markets because of its optimal combination of safety, efficacy and economical price that places it in reach of more patients and health providers."

As part of its commercialization efforts, Viridis BioPharma has sponsored clinical trials to demonstrate the efficacy of Microfoam dressings, the first of which are nearing initial reporting. "India tops the diabetes sufferers list as per World Health Organization (WHO) figures and consequently chronic diabetic wounds and ulcers. Quick-Med's NIMBUS Technology applied through Microfoam dressing shows remarkable relief in burn and wound cases and particularly in diabetic chronic wounds, as well as in venous and pressure ulcers, in an Indian clinical trial," commented Dr. Dilip Mehta, CEO of Viridis BioPharma Pvt. Ltd. "The Microfoam dressing offers an opportunity to help prevent bacterial infections, with affordable products, that are accessible to a much wider patient base than competing products, many of which are based on silver. Initial clinical observations on Microfoam cite that wounds show faster healing with Microfoam than with conventional treatments."

About NIMBUS

Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received *De Novo* FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, catheters, and contact lenses.

About Viridis BioPharma Pvt. Ltd

Through strategic associations with international pharmaceutical and biopharma companies, Viridis BioPharma Pvt. Ltd. commercializes products with therapeutic efficacy and growth potential in the Indian subcontinent and delivers a range of clinically-proven products to enable people to live better and more active lives. Viridis currently manufactures and markets a number of medical devices for companies, manufactured under license for B. Braun, American BioTech Labs, and Bhabha Atomic Research Center (BARC). For more information, see: www.viridisbiopharma.com

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. In addition to NIMBUS, Quick-Med's *Stay Fresh*[®] technology provides highly durable antimicrobial protection for laundered apparel and other textile applications and its NimbuDerm[™] technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.

registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc. Microfoam™ is a trademark of Viridis BioPharma Pvt. Ltd.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

CONTACT:

Quick-Med Technologies
Bernd Liesenfeld, President
(352) 379-0611
bliesenfeld@quickmedtech.com

Source: Quick-Med Technologies, Inc.